Orikine Bio, the Barcelona-based biotechnology company developing next-generation immunotherapies, has appointed Larry Edwards as Chairman of its Board of Directors, effective 1 January 2026.

Indero, a contract research organisation (CRO) specialising in dermatology and rheumatology, has announced the completion of an internally funded study introducing a novel approach to early-phase evaluation of topical new chemical entities (NCEs). The method applies quantitative gene expression analysis to generate efficacy signals within days rather than the weeks or months typically required by […]

Fresenius Kabi and TQ Therapeutics have entered into a strategic-development agreement aimed at improving the scalability and efficiency of cell and gene therapy (CGT) manufacturing. The agreement grants Fresenius Kabi an exclusive licence to develop, manufacture, and distribute products incorporating TQ Therapeutics’ proprietary cell selection technology.

iXCells Biotechnologies has appointed Steve Smith as Chief Executive Officer, elevating him from his previous role as Chief Commercial Officer (CCO) as the San Diego-based company expands its induced pluripotent stem cell (iPSC) preclinical services portfolio.